Merck’s Covid-19 Pill Shows Promise Against Omicron

Merck’s Covid-19 Pill Shows Promise Against Omicron

[ad_1] Merck cited six preclinical studies performed by researchers outside the company. The examples include research published this week in the New England Journal of Medicine that found molnupiravir among several Covid-19 antiviral drugs that “may show efficacy for treating patients infected with the Omicron variant.” Molnupiravir, which was cleared for use in the U.S. […]

Continue Reading
Merck's COVID-19 pill active against Omicron in lab studies

Merck’s COVID-19 pill active against Omicron in lab studies

[ad_1] An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS Register now for FREE unlimited access to Reuters.com Register […]

Continue Reading